Conferences - Results from #8340

#AUA15 - Crossfire: Controversies in Urology: Neuromodulation should be the first choice over botulinum toxin for idiopathic detrusor overactivity - Session Highlights May 19, 2015

#AUA15 - Role contemporary pre-cystectomy nomograms at predicting locally advanced and metastatic urothelial bladder cancer - Session Highlights May 19, 2015

Radium-223 dichloride in expanded-access setting in the United States: Overall and concurrent experience with abiraterone or enzalutamide - Session Highlights May 19, 2015

#AUA15 - Do primary hormonal therapy outcomes predict subsequent response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer? - Session Highlights May 19, 2015

#AUA15 - Best of Abstracts: Is retropubic mid-urethral sling safe and effective for patients with Valsalva voiding? - Session Highlights May 19, 2015

#AUA15 - Magnetic resonance imaging/ultrasound fusion-guided biopsy detects clinically significant prostate cancer in the central gland correlating with the index lesion - Session Highlights May 19, 2015

#AUA15 - Quality of advanced cancer care in an integrated urology/palliative care clinic - Session Highlights May 19, 2015

#AUA15 - The consequences of delaying stone treatment - Session Highlights May 19, 2015

#AUA15 - Prior bladder outflow surgery or large prostate volume does not adversely affect biochemical recurrence-free survival in low dose rate brachytherapy: An intermediate term analysis - Session Highlights May 19, 2015

#AUA15 - Risk stratification for adverse outcomes following renal mass excision - Session Highlights May 19, 2015

#AUA15 - Effect of abiraterone acetate and low dose prednisone on prostate-specific antigen in patients with non-metastatic castration-resistant prostate cancer: The results from Impact of Abiraterone Acetate in Prostate-Specific Antigen core study May 19, 2015

#AUA15 - Assessment of corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate to metastatic castration-resistant prostate cancer patients - Session Highlights May 19, 2015

#AUA15 - Exploring the incidence of abiraterone acetate withdrawal responses - Session Highlights May 19, 2015

#AUA15 - Novel antiandrogen ARN-509 in high-risk nonmetastatic castration-resistant prostate cancer - Session Highlights May 19, 2015

#AUA15 - ALP and bone scan flare following enzalutamide treatment of castration resistant prostate cancer (CRPC) with bone metastasis - Session Highlights May 19, 2015

#AUA15 - Best of Abstracts: Declining rates of retroperitoneal lymph node dissection for Stage I non-seminomatous germ cell tumors: Results from the National Cancer Database - Session Highlights May 19, 2015

#AUA15 - Societe Internationale D’Urologie (SIU) Lecture: Redefining optimal surgical management of muscle invasive bladder cancer - Session Highlights May 19, 2015

#AUA15 - State-of-the-Art Lecture: Bacillus Calmette-Guerin (BCG) refractory carcinoma in situ (CIS) of the bladder - Session Highlights May 19, 2015

#AUA15 - State-of-the-Art Lecture: Contemporary update on treatment of non-invasive bladder cancer - Session Highlights May 19, 2015

#AUA15 - AUA census highlights state of urology workforce May 19, 2015

Page 418 of 492

email news signup